GCM
ABCL icon

Gladius Capital Management’s AbCellera Biologics ABCL Stock Holding History

Gladius Capital Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,361
Closed -$25.3K – 362
2023
Q1 		$25.3K Buy
+3,361
New +$30.5K ﹤0.01% 309

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Gladius Capital Management's ABCL Position: Q2 2023 in Review

Gladius Capital Management sold out of AbCellera Biologics (ABCL) in Q2 2023, closing a stake of 3,361 shares — an estimated $25.3K sold.

Gladius Capital Management first reported a position in ABCL in Q1 2023 and held it in 1 quarter. The position peaked at $25.3K in Q1 2023. 169 funds tracked by Wall St. Rank hold ABCL as of Q2 2023.

  • Gladius Capital Management reported no remaining AbCellera Biologics position as of Q2 2023 after selling out during the quarter.
  • Gladius Capital Management sold 3,361 AbCellera Biologics shares in Q2 2023, an estimated $25.3K.
  • Gladius Capital Management first reported a position in AbCellera Biologics in Q1 2023 and held it in 1 quarter.
  • Gladius Capital Management's AbCellera Biologics position peaked at $25.3K in Q1 2023.
  • 169 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2023.

Based on Gladius Capital Management's 13F filing for Q2 2023, filed 8 Aug 2023.